EligibleTrials

NO Re-excision MelanomA - NORMA 2

Recruiting · NCT07530887 · Interventional (participants receive a specific treatment) · Lead sponsor: Marieke Goodijk

View the official record on ClinicalTrials.gov →
Melanoma

Interventions studied

No re-excisionRe-excision

What this trial is about

This multicenter, phase III randomized controlled trial evaluates whether omitting re-excision after complete primary excision of cutaneous melanoma affects patient outcomes. A total of 1,749 patients with pT1b-pT4b cutaneous melanoma without evidence of metastases will be randomized to either standard re-excision according to current guidelines or no re-excision. Sentinel lymph node biopsy and adjuvant systemic therapy will be performed as indicated in both groups. The primary objective is to compare relapse-free survival (RFS) between the two groups. Secondary objectives include comparisons of overall survival (OS), local recurrence rates, recurrence of in-transit and lymph node metastases, distant metastasis-free survival (DMFS), surgical morbidity, quality of life, and health economic outcomes.

Who can take part

Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

21 locations listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.